[1]Schubert ML, Moghimi R. Gastrointestinal stromal tumor (GIST) [J]. Curr Treat Options Gastroenterol, 2006,9(2):181-188.
[2]Rubin BP, Heinrich MC, Corless CL. Gastrointestinal strom-
al tumor [J]. Lancet, 2007, 369(19): 1731-1741.
[3]Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastroin-
testinal smooth-muscle (stromal) tumors: dependence on anatmic site [J]. Am J Surg Pathol,1999,23(1):82-87.
[4]中国胃肠道间质瘤病理专家组. 中国胃肠道间质瘤病理共识意见 [J]. 中华病理学杂志, 2007, 36(10): 704-707.
[5]DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gast-
rointestinal stromal tumors: recurrence patterns and prognostic factors for survival [J]. Ann Surg, 2000, 231(1):51-58.
[6]Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and
molecular genetic study of 906 cases before imatinib with long-term follow-up [J]. Am J Surg Pathol, 2006, 30(4):477-489.
[7]Streutker CJ,Huizinga JD,Driman DK,et al. Interstitial cells of Cajal in health and disease. Part Ⅱ: ICC and gastrointestinal stromal tumors [J].
Histopathology, 2007,50(2): 190-202.
[8]Kirsch R and Gao ZH. Gastrointestinal stromal tumors: dia-
gnostic challenges and practical approach to differential diagnosis [J]. Adv Anat Pathol, 2007,14(4): 261-285.
[9]Heinrich MC,Corless CL,Demetri GD,et al.Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J]. J Clin
Oncol, 2003, 21(23): 4342-4349.
[10]Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors [J]. Cancer Res, 2001, 61(22): 8118-8121.
[11]Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with
metastatic behavior of gastrointestinal stromal tumors [J]. Int J Cancer, 2003,106(6): 887-895.
[12]Raut CP, Morgan JA, Ashley SW. Current issues in gastr-
ointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease [J]. Curr Opin Gastroenterol, 2007,
23(2): 149-158.
[13]Debiec-Rychter M, Wasag B, Stul M, et al.Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity [J]. J Pathol, 2004,
202(4): 430-438.
[14]Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications [J]. Am J Surg
Pathol, 2004, 28(7): 889-894.
[15]Heinrich MC, Corless CL,Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors [J]. Science, 2003, 299(5607): 707-710.
[16]Motegi A, Sakurai S, Nakayama H, et al. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for
identifying KIT-negative tumors [J]. Pathol Int, 2005,55(3):106-112.
[17]West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA
mutation status [J]. Am J Pathol, 2004,165(1): 107-113.
[18]相小松,李幼生. 胃肠道间质瘤的研究进展 [J]. 医学研究生学报, 2005, 18(7): 650-656.
[19]Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at diff erent sites [J]. Semin Diagn Pathol, 2006, 23(2): 70-83.
[20]Demetri GD, Von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J]. N Engl J Med, 2002,
347(7): 472-480.
[1]王绍娟,王智涛,刘 钊,等.多层螺旋CT在胃肠道间质瘤恶性风险评估中的价值[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):226.
WANG Shao-juan,WANG Zhi-tao,LIU Zhao,et al.Prediction of malignancy degree of gastrointestinal stromal tumor with multi-slice CT[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(01):226.